Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Ethotoin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | EP300 | Q09472 | 1/20 | 0.47 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethotoin SCHEMBL34301 | 1.00 | LMNA (1.00) | LMNAADORA3ALDH1A1EP300CREBBP | |
| SCHEMBL11017764 | 0.85 | LMNA (0.73) | LMNAADORA3ALDH1A1TDP1KMT2A | |
| SCHEMBL11459127 | 0.83 | LMNA (0.71) | LMNAADORA3ALDH1A1EP300CREBBP | |
| Phenytoin SCHEMBL4657062 | 0.83 | LMNA (0.68) | LMNAADORA3ALDH1A1EP300CREBBP | |
| Ethotoin SCHEMBL6136639 | 0.82 | LMNA (0.67) | LMNAADORA3ALDH1A1EP300CREBBP | |
| SCHEMBL22265963 | 0.81 | LMNA (0.68) | LMNAADORA3ALDH1A1TSHRMEN1 | |
| SCHEMBL20459536 | 0.80 | LMNA (0.66) | LMNAADORA3ALDH1A1EP300CREBBP | |
| SCHEMBL5148364 | 0.79 | LMNA (0.66) | LMNAADORA3ALDH1A1EP300CREBBP | |
| SCHEMBL17622943 | 0.79 | LMNA (0.66) | LMNAADORA3ALDH1A1EP300CREBBP | |
| SCHEMBL11096386 | 0.79 | LMNA (0.66) | LMNAADORA3ALDH1A1EP300CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5779 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137654-A1 | COMPOUNDS AND METHODS FOR TREATING AN EPILEPTIC DISORDER | THE REGENTS OF THE UNIV OF CALIFORNIA (US) | 2026-05-21 | — | — | US | claimed |
| US-12594256-B2 | A19-144, A2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapy | ANAVEX LIFE SCIENCES CORP. (US) | 2026-04-07 | — | — | US | claimed |
| US-20260083706-A1 | 5HT AGONISTS FOR TREATING DISORDERS | UNIV CALIFORNIA (US) | 2026-03-26 | — | — | US | claimed |
| EP-4696377-A2 | 5HT AGONISTS FOR TREATING DISORDERS | The Regents of the University of California (US) | 2026-02-18 | — | — | EP | claimed |
| US-12498384-B2 | Biomarkers and methods for evaluation and treatment of epileptic vs non-epileptic seizures / no seizures / psychogenic non-epileptic seizures | COGNIZANCE BIOMARKERS, INC. (US) | 2025-12-16 | — | — | US | claimed |
| EP-4043016-B1 | THE 5HT AGONIST CLEMIZOLE FOR USE IN TREATING EPILEPSY DISORDERS | UNIV CALIFORNIA (US) | 2025-10-29 | — | — | EP | claimed |
| US-12447144-B2 | 5HT agonists for treating disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-10-21 | — | — | US | claimed |
| US-12419866-B2 | Compounds and methods for treating an epileptic disorder | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-09-23 | — | — | US | claimed |
| EP-3518975-B1 | FORMULATION COMPRISING FENFLURAMINE AND CANNABIDIOL AND ITS USE IN THE TREATMENT OF SEIZURES | ZOGENIX INTERNATIONAL LTD (GB) | 2025-04-09 | — | — | EP | claimed |
| EP-4465051-A2 | BIOMARKERS AND METHODS FOR EVALUATION AND TREATMENT OF EPILEPTIC VS NON-EPILEPTIC SEIZURES / NO SEIZURES / PSYCHOGENIC NON-EPILEPTIC SEIZURES | Cognizance Biomarkers, Inc. (US) | 2024-11-20 | — | — | EP | claimed |
| US-4992443-A | Method of treating motion sickness | CHELEN WILLIAM (US) | 1991-02-12 | — | — | US | claimed |
| US-4911931-A | Fluorine source and mitogenic hydratoin | BAYLINK DAVID J (US) | 1990-03-27 | — | — | US | claimed |
| US-4824850-A | DIHYDROPYRIDINE-PYRIDINIUM SALT REDOX CARRIER | UNIVERSITY OF FLORIDA (US) | 1989-04-25 | — | — | US | claimed |
| WO-1989000856-A1 | PHARMACEUTICAL COMBINATION FOR TREATMENT OF BONE-WASTING DISEASES | OSTEOTECH CORPORATION (US) | 1989-02-09 | — | — | WO | claimed |
| EP-0302714-A2 | Pharmaceutical composition for treatment of bone-wasting diseases | OSTEOTECH CORPORATION (US) | 1989-02-08 | — | — | EP | claimed |
| EP-0224283-A2 | Brain-specific drug delivery | UNIVERSITY OF FLORIDA (US) | 1987-06-03 | — | — | EP | claimed |
| EP-0222425-A2 | Brain-specific drug delivery | UNIVERSITY OF FLORIDA (US) | 1987-05-20 | — | — | EP | claimed |
| EP-0218300-A2 | Brain-specific drug delivery | UNIVERSITY OF FLORIDA (US) | 1987-04-15 | — | — | EP | claimed |
| EP-0110955-A1 | BRAIN-SPECIFIC DRUG DELIVERY. | UNIV FLORIDA (US) | 1984-06-20 | — | — | EP | claimed |
| WO-1983003968-A1 | BRAIN-SPECIFIC DRUG DELIVERY | UNIVERSITY OF FLORIDA (US) | 1983-11-24 | — | — | WO | claimed |